News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 11 - 02

Breaking the "Double Ten Law": How AI is Rewriting the Underlying Logic of New Drug R&D

Introduction: AI pharma is moving from "proof of concept" to "value realization." This article breaks down how AIDD is reconstructing the entire value chain of new drug R&D, and through Nvidia's investment map, reveals the ecosystem landscape of this track.Part 1　Foreword: When "Alchemy" Meets "Code," the "Impossible Triangle" Is Being BrokenOn the investment map of biomedicine, we are accustomed to using "ten years, one billion dollars, one-tenth" to describe the brutal law of new drug R&D: a new drug takes an ave...

浏览次数：0

查看详情>>

发布时间: 2026 - 10 - 30

Monthly News | October 2026: China's First Auditory Brainstem Implant Approved for Market, Three Financings Make New Progress

Recently, the Central Committee of the Communist Party of China and the State Council issued the Opinions on Developing New Quality Productive Forces. The Opinions pointed out that financial innovation product supply should be increased; angel investment, venture capital, and private equity investment should be encouraged and regulated; the guiding and driving role of government investment funds should be better leveraged; support policies for long-term capital to invest early, in small businesses, for the long term, and in hard technology should be improved; and patient capital should be expa...

浏览次数：3

查看详情>>

发布时间: 2026 - 10 - 28

Beyond the 30% LBA: Another Answer Sheet from Efung's Portfolio Companies at ESMO 2026

At the 2026 ESMO Annual Meeting, 29 of the 96 Late-Breaking Abstracts (LBAs) came from China, accounting for about 30%, with 5 entering the Presidential Session—both the number and proportion reaching historic highs. This is a visible marker of Chinese innovative drugs "being seen." [1]But "being seen" is not only measured by LBAs. Efung's portfolio companies presented another answer sheet at this year's ESMO: Huahao Zhongtian announced at ESMO a Phase III head-to-head study (2666P) comparing its drug with docetaxel in NSCLC patients who had failed prior platinum-co...

浏览次数：2

查看详情>>

发布时间: 2026 - 10 - 26

Efung News | First in China! Yifeng Portfolio Company Nurotron's Auditory Brainstem Implant Approved by NMPA for Marketing

On October 19, the innovative auditory brainstem implant product independently filed by Zhejiang Nurotron Neuroelectronic Technology Co., Ltd. officially received registration approval from the National Medical Products Administration (NMPA).The product consists of a stimulator, receiving coil, intracranial electrode array, extradural plate electrode, extradural ring electrode, and internal magnet. It is used in conjunction with the cochlear implant speech processor produced by the company. After decoding the digital information from the external speech processor, it converts it into current p...

浏览次数：2

查看详情>>